This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (8)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Clinically Indicated and Economically Wise!

M. Brian Fennerty, MD

Arch Intern Med. 1995;155(18):1929-1931.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

IN THIS ISSUE of the ARCHIVES, O'Brien and colleagues¹ use the increasingly popular technique of decision analysis to conclude that from an economic standpoint, it is much less costly to treat uncomplicated duodenal ulcer disease associated with Helicobacter pylori by eradicating the infection rather than by continuing the time-honored practice of intermittent or continuous maintenance therapy with H₂ receptor antagonists. Their article underscores many important clinical and economic issues regarding peptic ulcers and H pylori, yet leaves many issues unanswered.

See also page 1958

Helicobacter pylori was first described in 1983 by Warren² and Marshall³ in association with active chronic gastritis. Shortly thereafter, H pylon's association with duodenal and gastric ulcers was noted, leading to an incredible proliferation of interest as manifested by the dominance of H pylori in the ulcer literature for the past decade.⁴ Eradication of H pylori has been unequivocally proved to . . . [Full Text PDF of this Article]

Author Affiliations
Division of Gastroenterology Oregon Health Sciences University 3181 SW Sam Jackson Park Rd PV310 Portland, OR 97201-3098

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?